Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Up 7.3% in March

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 6,060,000 shares, a growth of 7.3% from the March 15th total of 5,650,000 shares. Based on an average daily volume of 540,200 shares, the short-interest ratio is currently 11.2 days. Approximately 12.3% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.00.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of DCPH. Goldman Sachs Group Inc. lifted its stake in Deciphera Pharmaceuticals by 356.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 3,663,819 shares of the company's stock valued at $48,179,000 after buying an additional 2,861,642 shares in the last quarter. Federated Hermes Inc. lifted its stake in Deciphera Pharmaceuticals by 125.5% in the 1st quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company's stock valued at $18,161,000 after buying an additional 1,090,368 shares in the last quarter. BlackRock Inc. lifted its stake in Deciphera Pharmaceuticals by 27.6% in the 1st quarter. BlackRock Inc. now owns 4,845,376 shares of the company's stock valued at $44,917,000 after buying an additional 1,047,807 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Deciphera Pharmaceuticals by 176.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company's stock valued at $16,482,000 after buying an additional 651,800 shares in the last quarter. Finally, Armistice Capital LLC lifted its stake in shares of Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock worth $83,876,000 after purchasing an additional 588,000 shares during the period. Hedge funds and other institutional investors own 70.96% of the company's stock.

Deciphera Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:DCPH traded down $0.12 during trading on Wednesday, hitting $14.72. 378,846 shares of the stock were exchanged, compared to its average volume of 523,282. The company has a fifty day moving average price of $15.68 and a two-hundred day moving average price of $14.19. The company has a market cap of $1.19 billion, a PE ratio of -6.43 and a beta of 0.39. Deciphera Pharmaceuticals has a 12-month low of $9.90 and a 12-month high of $17.73.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. The business had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.60) EPS. Equities research analysts anticipate that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.